Breaking News, Collaborations & Alliances

TriLink, Quantoom Sign License & Supply Agreement for mRNA Capping Technology

Aim to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide.

Author Image

By: Charlie Sternberg

Associate Editor

TriLink BioTechnologies, a global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics, under which Quantoom will have access to TriLink’s CleanCap mRNA capping technology for integration in its Ntensify (sa)mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters